Reneo Pharmaceuticals, Inc. – NASDAQ:RPHM
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Reneo Pharmaceuticals stock price monthly change
-14.94%
month
Reneo Pharmaceuticals stock price quarterly change
-14.45%
quarter
Reneo Pharmaceuticals stock price yearly change
-80.29%
year
Reneo Pharmaceuticals key metrics
Market Cap | 60.84M |
Enterprise value | 146.56M |
P/E | -3.19 |
EV/Sales | N/A |
EV/EBITDA | -2.82 |
Price/Sales | N/A |
Price/Book | 1.65 |
PEG ratio | -0.05 |
EPS | -2.17 |
Revenue | N/A |
EBITDA | -77.45M |
Income | -70.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeReneo Pharmaceuticals stock price history
Reneo Pharmaceuticals stock forecast
Reneo Pharmaceuticals financial statements
| Jun 2023 | 0 | -19.53M | |
|---|---|---|---|
| Sep 2023 | 0 | -19.19M | |
| Dec 2023 | 734K | -23.55M | -3208.99% |
| Mar 2024 | 0 | -8.42M |
| Sep 2025 | 7.96M | -10.46M | -131.28% |
|---|---|---|---|
| Oct 2025 | 7.96M | -10.34M | -129.78% |
| Dec 2025 | 15.96M | -6.42M | -40.22% |
| Dec 2025 | 15.96M | -6.34M | -39.76% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 148039000 | 15.51M | 10.48% |
|---|---|---|---|
| Sep 2023 | 130388000 | 15.44M | 11.84% |
| Dec 2023 | 107436000 | 18.82M | 17.52% |
| Mar 2024 | 84639000 | 3.39M | 4.01% |
| Jun 2023 | -16.11M | -69.01M | 63.81M |
|---|---|---|---|
| Sep 2023 | -18.76M | 21.25M | 173K |
| Dec 2023 | -19.75M | 39.77M | -4.12M |
| Mar 2024 | -21.01M | 13.75M | 0 |
Reneo Pharmaceuticals alternative data
| Aug 2023 | 48 |
|---|---|
| Sep 2023 | 51 |
| Oct 2023 | 51 |
| Nov 2023 | 51 |
| Dec 2023 | 55 |
| Jan 2024 | 55 |
| Feb 2024 | 55 |
| Mar 2024 | 55 |
| Apr 2024 | 55 |
| May 2024 | 55 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Reneo Pharmaceuticals other data
26.18%
-41.12%
of RPHM is owned by hedge funds
18
-14
6.41M
-10.07M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 100000 |
| Aug 2023 | 0 | 15625 |
| May 2024 | 414281 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LEONARD BRADEN MICHAEL 10 percent owner | Common Stock | 335,000 | $1.54 | $515,900 | ||
Purchase | LEONARD BRADEN MICHAEL 10 percent owner | Common Stock | 79,281 | $1.56 | $123,678 | ||
Option | HALL ASHLEY officer: Chief De.. | Stock option (right to buy) | 15,625 | $1.8 | $28,125 | ||
Option | HALL ASHLEY officer: Chief De.. | Common Stock | 15,625 | $1.8 | $28,125 | ||
Sale | HALL ASHLEY officer: Chief De.. | Common Stock | 15,625 | $6.28 | $98,063 | ||
Sale | NOVO HOLDINGS A/S 10 percent owner | Common Stock | 100,000 | $7.1 | $709,700 | ||
Purchase | O'DONNELL NIALL director | Common Stock | 125,000 | $8 | $1,000,000 | ||
Purchase | CRUSE MICHAEL officer: Chief Operating Officer | Common Stock | 7,500 | $3.39 | $25,448 | ||
Purchase | CRUSE MICHAEL officer: Chief Operating Officer | Common Stock | 3,212 | $3.21 | $10,307 | ||
Option | GREY MICHAEL G director, officer.. | Stock option (right to buy) | 50,000 | $1.97 | $98,500 |
| Insider | Compensation |
|---|---|
| Mr. Gregory J. Flesher (1970) Pres, Chief Executive Officer & Director | $528,780 |
| Dr. Alejandro Dorenbaum (1961) Chief Medical Officer | $477,650 |
| Ms. Wendy S. Johnson (1952) Consultant | $458,400 |
-
When is Reneo Pharmaceuticals's next earnings date?
Unfortunately, Reneo Pharmaceuticals's (RPHM) next earnings date is currently unknown.
-
Does Reneo Pharmaceuticals pay dividends?
No, Reneo Pharmaceuticals does not pay dividends.
-
How much money does Reneo Pharmaceuticals make?
Reneo Pharmaceuticals has a market capitalization of 60.84M.
-
What is Reneo Pharmaceuticals's stock symbol?
Reneo Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RPHM".
-
What is Reneo Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Reneo Pharmaceuticals?
Shares of Reneo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Reneo Pharmaceuticals's key executives?
Reneo Pharmaceuticals's management team includes the following people:
- Mr. Gregory J. Flesher Pres, Chief Executive Officer & Director(age: 55, pay: $528,780)
- Dr. Alejandro Dorenbaum Chief Medical Officer(age: 64, pay: $477,650)
- Ms. Wendy S. Johnson Consultant(age: 73, pay: $458,400)
-
How many employees does Reneo Pharmaceuticals have?
As Jul 2024, Reneo Pharmaceuticals employs 8 workers, which is 85% less then previous quarter.
-
When Reneo Pharmaceuticals went public?
Reneo Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 8 Apr 2021.
-
What is Reneo Pharmaceuticals's official website?
The official website for Reneo Pharmaceuticals is reneopharma.com.
-
Where are Reneo Pharmaceuticals's headquarters?
Reneo Pharmaceuticals is headquartered at 18575 Jamboree Road, Irvine, CA.
-
How can i contact Reneo Pharmaceuticals?
Reneo Pharmaceuticals's mailing address is 18575 Jamboree Road, Irvine, CA and company can be reached via phone at +61 97333852.
Reneo Pharmaceuticals company profile:
Reneo Pharmaceuticals, Inc.
reneopharma.comExchange:
NASDAQ
Full time employees:
8
Industry:
Biotechnology
Sector:
Healthcare
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
18575 Jamboree Road
Irvine, CA 92612
Irvine, CA 92612
CIK: 0001637715
ISIN: US75974E1038
CUSIP: 75974E103
